Relationship Between Pelvic Angle, Femoral Anteversion, and Hip Muscle Strength Ratios in Bladder-bowel Dysfunction

February 9, 2024 updated by: Halil Tugtepe

Relationship Between Pelvic Angle, Femoral Anteversion, and Hip Muscle Strength Ratios in Children With Bladder-bowel Dysfunction

Bladder and bowel dysfunction is a combination of lower urinary tract and bowel dysfunction seen in children over 5 years of age without identifiable or discernible neurological abnormalities. The proper functioning of the bladder, bowel, nerves, pelvic floor muscles and related anatomical structures provides the bowel and lower urinary tract function. Dysfunction of any structure of the pelvic floor can potentially cause to bladder and bowel dysfunction. The ability of the pelvic floor muscles to perform the correct contraction and relaxation function is also closely related to the position of the pelvis, muscle strength of the hip muscles, and femoral anteversion. Disruption of one of the links forming the chain causes a change in the mobility and stability of all mechanically related structures and may affect the optimal force that the pelvic floor muscles can produce.

As far as investigators know, there is no study in the literature examining the relationship between BBD and pelvic angle, femoral anteversion angle, femoral internal/external rotation angle ratio and hip muscle strength ratios in children with bladder-bowel dysfunction. Considering the close relationship between pelvis position, hip muscle strength, and femoral anteversion with the pelvic floor, investigators think that this relationship should be evaluated in children with BBD and will contribute to the literature.

Study Overview

Detailed Description

Bladder and bowel dysfunction (BBD) is a combination of lower urinary tract (LUT) and bowel dysfunction seen in children over 5 years of age without identifiable or discernible neurological abnormalities. Constipation and fecal incontinence are common bowel dysfunctions. Common lower urinary tract dysfunction (LUTD) symptoms of BBD include dysuria, urgency, urinary frequency, difficulty in initiating urine, daytime incontinence, enuresis, straining, delayed voiding, and urinary retention. Urological conditions such as overactive bladder, underactive bladder and dysfunctional voiding can also be part of BBD.

The proper functioning of the bladder, bowel, nerves, pelvic floor muscles and related anatomical structures provides the bowel and LUT function. The pelvic floor is a structure located at the base of the pelvis, consisting of smooth and striated muscle sphincters, endopelvic fascia, connective tissue and ligaments, mucosal and vascular tissues, levator ani and more superficial perineal muscles. It actively supports the pelvic organs (bladder, bowel, uterus) and provides continence. Dysfunction of any structure of the pelvic floor can potentially cause to bladder and bowel dysfunction.

The ability of the pelvic floor muscles to perform the correct contraction and relaxation function is also closely related to the position of the pelvis, muscle strength of the hip muscles, and femoral anteversion. The pelvis and lower extremity consist of interconnected closed chain structures. The movement of any link in the chain depends on the movement of the other links. For this reason, disruption of one of the links forming the chain causes a change in the mobility and stability of all mechanically related structures and may affect the optimal force that the pelvic floor muscles can produce.

As far as investigators know, there is no study in the literature examining the relationship between BBD and pelvic angle, femoral anteversion angle, femoral internal/external rotation angle ratio and hip muscle strength ratios in children with bladder-bowel dysfunction. Considering the close relationship between pelvis position, hip muscle strength, and femoral anteversion with the pelvic floor, investigators think that this relationship should be evaluated in children with BBD and will contribute to the literature.

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey, 34353
        • Private Tugtepe Pediatric Urology Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 years to 12 years (Child)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Children who are between 5-12 years old, diagnosed with bladder bowel dysfunction.

Description

Inclusion Criteria:

  • To be between the ages of 5-12
  • To be diagnosed with bladder- bowel dysfunction

Exclusion Criteria:

  • To be younger than 5 years old
  • To have an orthopedic disease that would prevent the evaluation
  • To have anatomical changes in the urinary system
  • To have having a neurological disorder
  • To have cognitive impairment and mental retardation
  • To have an orthopedic surgery that can change pelvis and lower extremity biomechanics

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Children diagnosed with bowel and bladder dysfunction
Children who are between the ages of 5-12 and diagnosed with bladder- bowel dysfunction by pediatric urologist.

Assessments Children whose physical examination has been completed and diagnosed with BBD will be evaluated with following assessments.

Demographic Data Form Questionnaire Forms Dysfunctional Voiding and Incontinence Scoring System Bladder Diary Bowel Diary EMG-uroflowmetry Ultrasonography

Post Voiding Residual Measurement:

Bladder wall thickness

Pelvic Floor Muscle Activation Measurement:

Pelvic Floor Muscle Strength Assessment:

Hip agonist-antagonist muscle ratios Pelvic angle measurement Femoral anteversiyon angle measurement

Femoral internal and external rotation angle:

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Femoral anteversion angle measurement
Time Frame: Baseline
Hip anteversion was measured using the Craig test with the subject in the prone position and the knee flexed to 90°. The examiner passively rotates the hip, palpating the trochanter major, until the most prominent part of the trochanter reaches its most lateral position. The angle between the true vertical and the shaft of the tibia was measured to the nearest degree, using a Accurate Compass smartphone inclinometer.
Baseline
Pelvic angle measurement
Time Frame: Baseline
The inferior prominence of the anterior superior iliac spine (ASIS) and the most prominent aspect of the posterior superior iliac spine (PSIS) were identified with palpation, and pelvic angle was measured as the angle formed between the horizontal plane and a line from ASIS and PSIS landmarks using an inclinometer (Performance Attainment Associates, St Paul, MN). A positive value reflected an anterior pelvic tilt (ASIS sitting lower than the PSIS).
Baseline
Hip agonist-antagonist muscle ratios
Time Frame: Baseline
In the isometric muscle strength measurement procedure, each test position was evaluated with 2 repetitions of submaximal force for familiarization and 3 evaluations were taken with maximal force. Each test lasted 5 seconds, with 30-second breaks between trials. A 1-minute break was given between different measurements. MicroFET(Draper, UT) hand dynamometer was used for muscle strength measurement. The order of strength testing was randomized. The dynamometer is fixed to the leg with the help of a strap. Force values are measured in kilograms and normalized to body mass using the following formula:(kg power/kg body mass)x100. The intrarater reliability study will be completed before participants' measurements begin to be taken. Hip abductor, adductor, flexor, extensor, internal rotation, external rotation muscle strength is measured. Hip adductor/abductor, medial/lateral rotator, and flexor/extensor strength ratios muscle strength ratios will be evaluated.
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dysfunctional Voiding and Incontinence Scoring System
Time Frame: Baseline
Dysfunctional Voiding and Incontinence Scoring System (DVISS) is a 13-item questionnaire. Parents are the target audience. DVISS scores are based on the estimated odds ratio for each question between cases and controls. For example, 1 point is awarded if the odds ratio value is between 2 and 10, and 5 points if it is greater than 50. The total score can range from 0 to 35. A cut-off value of 8.5 shows 90% specificity and sensitivity in detecting BBD.
Baseline
EMG-uroflowmetry
Time Frame: Baseline
In the uroflowmetry evaluation, when the patient's urge to urinate occurs, urination will be requested into the AYMED® brand EMG uroflowmetry pot with a sensor system. Stool support will be provided to ensure suitable toilet position in children whose feet do not touch the ground during the test measurement. In order to minimize the external factors that will affect the voiding pattern, there will be no one other than the patient in the uroflowmetry room. The parameters obtained as a result of the measurement will enable us to interpret the bladder's emptying phase.
Baseline
Ultrasonography - Post Voiding Residual Measurement, Bladder thickness
Time Frame: Baseline
Telemed® brand transabdominal ultrasound device will be used, and measurements will be made from the suprapubic region. During the measurement, the patient will be positioned in the supine position and the knees will be slightly flexed and supported with a towel under the knee. The volume values in mm3 calculated by the probe in the coronal and sagittal regions will be automatically multiplied by the ultrasound system and the residual urine remaining in the bladder will be calculated in cc. The standard method should be used for pelvic voiding residual measurements.
Baseline
Pelvic Floor Muscle Activation Measurement:
Time Frame: Baseline

The pelvic floor physiotherapist positions the participant in the butterfly position with support under the legs while lying on their back. Before EMG evaluation, all participants are taught to perform isolated contraction and relaxation of the pelvic floor muscles without the use of accessory muscles by anus palpation. Two superficial electrodes (30 mm diameter (VS30)) are then placed bilaterally adjacent to the mucocutaneous line of the anus at 2 and 7 o'clock to prevent cross-talking (electrodes interference and artifact formation). The reference surface electrode is placed on the inside of the right thigh.

After proper placement of the electrodes, pelvic floor muscle activity will be measured with the NeuroTrac Myoplus4 Pro device.

Baseline
Pelvic Floor Muscle Strength Assessment:
Time Frame: Baseline

Manual muscle testing is a subjective assessment method. First, the child is taught to contract the pelvic floor muscles in the litotomy position (supine, butterfly position). The therapist places the index finger on the anus (perceiving contraction of the external anal sphincter), asking child's to contract the pelvic floor muscles as if she were holding child's stool or urine. The therapist then asks the child to contract the pelvic floor muscles as the muscles teach the correct contraction.

With the manual muscle test, the strength, fatigue time and endurance of the pelvic floor muscles are evaluated. Evaluation of pelvic floor muscles in children is evaluated by palpation over the external anal sphincter, and the following grading method is used.

Modified Oxford Scale 0= no contraction

1= vibration 2 = weak contraction 2+= contraction without movement 3 = contraction with movement 3+= strong contraction

Baseline
Femoral internal and external rotation angle
Time Frame: Baseline
Passive hip internal rotation and external rotation were measured with a standard goniometer, with the child lying face down on the table in the prone position. The thigh was carefully positioned to 0° hip abduction or adduction and the contralateral leg to approximately 20° abduction. Pelvis is stabilized by another physiotherapist and examiner measured range of motion by bringing the leg to a firm end point of both IR and ER. The measurement was made by passively bringing the leg to its end point in both internal and external rotation, without lifting the pelvis from the ground. Angle measurement will be made with Accurate Compass smartphone inclinometer.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Aygül Köseoğlu, PT, MSc, Tuğtepe Pediatric Urology Clinic
  • Study Chair: Tuğçe Atalay, PT, Tuğtepe Pediatric Urology Clinic
  • Study Chair: Ece Zeynep Saatçi, PT, Tuğtepe Pediatric Urology Clinic
  • Study Chair: Melis Ünal, PT, Tuğtepe Pediatric Urology Clinic
  • Study Chair: Halil Tuğtepe, MD, Prof Dr,, Tuğtepe Pediatric Urology Clinic
  • Study Director: Pelin Pişirici, PT, PhD, Bahçeşehir University Faculty of Health Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2022

Primary Completion (Actual)

September 1, 2023

Study Completion (Actual)

February 9, 2024

Study Registration Dates

First Submitted

November 21, 2021

First Submitted That Met QC Criteria

December 21, 2021

First Posted (Actual)

January 10, 2022

Study Record Updates

Last Update Posted (Actual)

February 12, 2024

Last Update Submitted That Met QC Criteria

February 9, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • TUGTEPEPUC

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bladder and Bowel Dysfunction, Femoral Anteversion

Subscribe